sar425899 glucagon glp-1 dual agonist sanofi Clinical relevance of dual agonist of glucagon and glucagon Effects on weight loss and

Description

Glucagon increases blood glucose levels, particularly during fasting, and facilitates the mobilization of energy reserves.Synthetic agonists like semaglutide and tirzepatide are stable peptides that specifically activate the receptors of these hormones, amplifying their beneficial effects on glycemic control and weight management

### Funding Statement SDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained

The agency will continue to work with state regulators, monitor the market, and

ConclusionGLP-1 medications can be a helpful tool for weight loss, but theyre not a one-size-fits-all solution

While newly approved pharmacotherapies such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) show efficacy, their clinical utility remains constrained by dose-dependent gastrointestinal complications, underscoring the urgent need for safer alternatives